SCHEMBL19658179

SCHEMBL19658179

O=C(CN1CCC(C(=O)ON2C(=O)CCC2=O)CC1)ON1C(=O)CCC1=O

nearest known ligand 0.34

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 7/20 0.34
▸ SMN1; SMN2 Q16637 3/20 0.34
▸ ALOX15 P16050 2/20 0.34
▸ GAA P10253 1/20 0.34
▸ KDM4E B2RXH2 2/20 0.33
▸ LMNA P02545 1/20 0.32
▸ CYP1A2 P05177 1/20 0.32
▸ POLB P06746 1/20 0.32
▸ CYP2D6 P10635 1/20 0.32
▸ CYP2C9 P11712 1/20 0.32
▸ CYP2C19 P33261 1/20 0.32
▸ KMT2A Q03164 2/20 0.32
▸ MEN1 O00255 1/20 0.32
▸ MAPT P10636 1/20 0.32
▸ NPSR1 Q6W5P4 1/20 0.32
▸ MGLL Q99685 1/20 0.31
▸ TSHR P16473 1/20 0.31
▸ MAPK1 P28482 1/20 0.31
▸ NPC1 O15118 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25355536 0.86 WNT1 (0.39) ALDH1A1SMN1; SMN2ALOX15GAAKDM4E
SCHEMBL17776064 0.80 MGLL (0.33) SMN1; SMN2KMT2AMGLL
SCHEMBL18751703 0.80 MGLL (0.33) SMN1; SMN2KMT2AMGLL
SCHEMBL17776136 0.80 MGLL (0.33) SMN1; SMN2KMT2AMGLL
SCHEMBL855021 0.80 MGLL (0.33) SMN1; SMN2KMT2AMGLL
SCHEMBL23903919 0.79 GSK3B (0.32) ALDH1A1POLBMAPT
SCHEMBL1241402 0.79 GAA (0.41) ALDH1A1SMN1; SMN2GAAKDM4EPOLB
SCHEMBL560792 0.78 HSD17B10 (0.39) ALDH1A1SMN1; SMN2KMT2AMEN1MGLL
SCHEMBL22849928 0.78 BRD4 (0.34) ALDH1A1LMNAKMT2AMEN1MGLL
SCHEMBL15518427 0.78 HSD17B10 (0.39) ALDH1A1SMN1; SMN2KMT2AMEN1MGLL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10689430-B2 Insulin receptor partial agonists MERCK SHARP & DOHME CORP. (US) 2020-06-23 — — US disclosed
US-20190177393-A1 INSULIN RECEPTOR PARTIAL AGONISTS MERCK SHARP & DOHME CORP. (US) 2019-06-13 — — US disclosed
WO-2017205309-A1 INSULIN RECEPTOR PARTIAL AGONISTS MERCK SHARP & DOHME CORP. (US) 2017-11-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190177393-A1 INSULIN RECEPTOR PARTIAL AGONISTS INSR, GPR119, IRS1 ALDH1A1 4716/4885SMN1; SMN2 3416/4885ALOX15 4361/4885
US-10689430-B2 Insulin receptor partial agonists INSR, GPR119, IRS1 ALDH1A1 4716/4885SMN1; SMN2 3416/4885ALOX15 4361/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback